MolPharm xPharm- The Comprehensive Pharmacology Reference

Home Help [Feedback] [For Subscribers] [Archive] [Search] --
 QUICK SEARCH:   [advanced]


     


Molecular Pharmacology Fast Forward
First published on November 29, 2007; DOI: 10.1124/mol.107.040931


This Article
Right arrow Full Text (PDF)
Right arrow Data Supplement
Right arrow All Versions of this Article:
mol.107.040931v1
73/3/697    most recent
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schwieger, I.
Right arrow Articles by Hermosilla, R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwieger, I.
Right arrow Articles by Hermosilla, R.


Received for publication August 15, 2007.
Revised November 26, 2007.
Accepted for publication November 26, 2007.

Derlin-1 and p97/VCP Mediate the ER-Associated Degradation of Human V2 Vasopressin Receptors

Isabel Schwieger 1, Katja Lautz 1, Eberhard Krause 2, Walter Rosenthal 1, Burkhard Wiesner 2, Ricardo Hermosilla 1*

1 Charite-Universitatsmedizin Berlin 2 Leibniz-Institut fur Molekulare Pharmakologie

* Address correspondence to: E-mail: ricardo.hermosilla{at}charite.de

Abstract

The ER-associated degradation (ERAD), the main quality control pathway of the cell, is crucial for the elimination of unfolded or misfolded proteins. Several diseases are associated with the retention of misfolded proteins in the early secretory pathway. Among them is X-linked nephrogenic diabetes insipidus, caused by mutations in the gene encoding the V2 vasopressin receptor (V2R). We studied the degradation pathways of three intracellularly retained V2R mutants with different misfolded domains in HEK293 cells. At steady state, the wild type V2R and the complex-glycosylated mutant G201D were partially located in lysosomes, while core-glycosylated mutants L62P and V226E were excluded from this compartment. In pulse-chase experiments, proteasomal inhibition stabilized the non- and core-glycosylated forms of all studied receptors. In addition, all mutants and the wild type receptor were found to be polyubiquitinylated. Non- and core-glycosylated receptor forms were located in cytosolic and membrane fractions, respectively, confirming the deglycosylation and retrotranslocation of ERAD substrates to the cytosol. Recently, distinct Derlin-1-dependent and -independent ERAD pathways have been proposed for proteins with different misfolded domains (cytosolic, extracellular and membrane) in yeast. Here we show for the first time that V2R mutants with different misfolded domains are able to co-precipitate the ERAD components p97/valosin-containing protein, Derlin-1 and the 26S proteasome regulatory subunit 7. Our results demonstrate the presence of a Derlin-1 mediated ERAD pathway degrading wild type and disease-causing V2R mutants with different misfolded domains in a mammalian system.


Key words: Vasopressin/Oxytocin, Receptor synthesis/trafficking, Receptor degradation, Fluorescence techniques, Mass Spectroscopy





Home Help [Feedback] [For Subscribers] [Archive] [Search] --
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2007 by the American Society for Pharmacology and Experimental Therapeutics